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tasis. The 1- and 5-year post-hepatic transplantation survival rates among patients 
subjected to bone scintigraphy were 81% and 69%, respectively; those among patients 
not subjected to scintigraphy were 78% and 62%, respectively (p = 0.25). The 1- and 
5-year post-HTx recurrence rates among patients subjected to bone scintigraphy were 
4.8% and 10.7%; those among patients not subjected to scintigraphy were 2.9% and 
10.1%, respectively (p = 0.46). Results: The cost generated by the current evaluation 
policies, US$ 27.582, did not result in the detection of any sub-clinical metastasis and 
therefore failed to provide positive cost-effectiveness. ConClusions: Clinical evi-
dence has demonstrated that bone scintigraphy did not provide aditional information 
about patient selection since the incidence of metastasis in early stages is very low. 
In our cohort, the use of scintigraphy in the assessment of patients with early stages 
of HCC and within the Milão criteria, included in a liver transplant list by dead donor, 
in a center in the south of Brazil, had zero benefit.
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objeCtives: To determine the cost-utility of continuing education for the man-
agement of patients with type 2 Diabetes Mellitus (T2DM), in Pernambuco - 
Brazil. Methods: It’s a cost-utility evaluation, using the Markov model to simulate 
the results in health scenarios, from the perspective of the health system. It was 
considered an analytic horizon of 20 years and selected the category of direct medi-
cal costs. Data were obtained from primary source, SERVIDIAH study, and secondary 
sources from health information systems and literature. The reference scenario 
represents the standard health care management performed in public health ser-
vices. The simulated scenarios for post-intervention’s results were based on the 
suggestion of consulted experts in regard the effectiveness of continuing education 
for health professionals in primary health care (PHC) for the patient’s complications 
reduction. Results: The average individual, representative Pernambuco’s popula-
tion, was female, 61 years old and diagnosed with T2DM for 8.7 years. These and 
other clinical characteristics that influence the calculation of the transition prob-
abilities were gathered from over 800 patients with T2DM from Pernambuco. For the 
reference scenario, the cost for one individual was calculated for the intervention’s 
first year, 2011: without complications (U$ 491.04), with microvascular complications 
(U$ 774.23), macrovascular complications (U$ 1,945.95) and both complications (U$ 
2,229.14). The incremental cost for the implementation of the intervention was 
U$ 242.42 per individual/year, later added to the cost for standard management 
in the post-intervention scenarios. At the cost-utility evaluation, only the first 
simulated scenario (Very Satisfactory Result) was cost-effective, with Incremental 
Cost-effectiveness Ratio (ICER) of U$ 7,362.70/QALY. ConClusions: The ICER pre-
sented suggests that the intervention isn’t a cost-effective alternative. Given the 
uncertainties about the effectiveness of continuing education for professionals in 
the PHC on the health of users, it is necessary to conduct in-depth studies on the 
association between these variables.
PRM26
ModEls UsEd in EConoMiC analysEs of tiCagREloR and PRasUgREl foR 
aCUtE CoRonaRy syndRoMEs: a stRUCtUREd REviEw
Law E.H., Sharma D., Pickard S.
University of Illinois at Chicago, Chicago, IL, USA
objeCtives: To critically appraise published pharmacoeconomic studies of 
two novel antiplatelet (AP) agents (ticagrelor and prasugrel) in the treatment 
of acute coronary syndromes (ACS). Methods: Key terms related to economic 
evaluations of ticagrelor and/or prasugrel were searched in EMBASE, MEDLINE and 
International Pharmaceutical Abstracts. English-language articles evaluating the 
use of these agents in adults with ACS were included. Studies assessing genotyp-
ing-guided treatments were excluded. Elements of each study were independently 
extracted based on the ISPOR Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) checklist by two reviewers. Results: Eleven (7 ticagrelor, 4 
prasugrel) studies were identified, 7 of which included both cost-effectiveness 
and cost-utility analysis. No comparisons were made between prasugrel and 
ticagrelor and each agent was compared to clopidogrel. The manufacturer of the 
novel AP funded all but one study. Most models were Markov-based simulations, 
with almost all studies adopting a healthcare system perspective and lifetime 
time horizon. Two randomized-control trials (RCTs), PLATO and TRITON-TIMI 38 
were most commonly cited for ticagrelor and prasugrel, respectively, with few 
non-RCTs used for clinical data input. While methods to derive the efficacy data 
were commonly reported, utility estimates varied for some health states between 
studies using the same data by the same sponsor. Both ticagrelor and prasugrel 
were deemed cost-effective vs. clopidogrel in base-case analyses. ConClusions: 
Studies would benefit from greater consistency in sources of costing data and 
estimates of utility values and decrements. There is a clear reliance on single mul-
tinational RCTs as the primary data source for the vast majority of model inputs, 
and the PLATO study has been heavily criticized for issues related to external 
validity. More independent, non-industry sponsored economic evaluations and 
real-world clinical data are required in the future. Reporting checklists do not 
capture these latent issues behind economic evaluations, as identified by our 
appraisal of the literature.
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further investigation as a way to detect, characterize, and address bias in retrospec-
tive samples.
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objeCtives: In clinical trials of early-stage prostate cancer, demonstration of an 
overall survival (OS) benefit is challenging because of prolonged patient survival. 
While the development of metastasis is a major milestone in the disease, payers 
are interested in understanding the clinical relevance of metastatic-free survival 
(MFS) as a surrogate endpoint and its relationship with long-term outcomes, in 
particular, OS. The objective of the current study was to identify empirical evi-
dence evaluating MFS in patients with prostate cancer. Methods: A structured 
literature review was conducted in PubMed (1999−2014) to identify clinical trials in 
prostate cancer using MFS as a primary endpoint, and clinical and observational 
studies that evaluated the association between MFS and OS. Results: Three 
published clinical trials used MFS as a primary endpoint. The studies employed 
varying definitions for MFS (e.g., bone metastasis only or bone and soft tissue 
metastasis). In one long-term study comparing adjuvant radiotherapy to usual 
care, both MFS and OS outcomes were significantly improved with radiotherapy, 
suggesting a relationship between these two endpoints. Four additional studies 
examined the association between MFS and OS. One study reported that dis-
tant metastasis at three years met the Prentice criteria for surrogacy of prostate 
cancer-specific survival at 10 years. A second study reported that MFS was one of 
four independent prognostic variables for OS in prostate cancer. The remaining 
two studies demonstrated that time to metastasis was significantly associated 
with prostate cancer-specific mortality. ConClusions: MFS has been used as 
the primary endpoint in several prostate cancer studies, providing support for the 
clinical relevance of this outcome. Current evidence from the literature suggests 
an association between MFS and OS, however additional research is needed to 
further investigate this relationship.
REsEaRCh on MEthods – Cost Methods
PRM23
ContRasting Cost-EffECtivEnEss REsUlts dERivEd fRoM 
ContEMPoRaRy sEts of altERnativE Risk EqUations in tyPE 2 diabEtEs
Foos V.1, Lamotte M.2, McEwan P.3
1IMS Health, Basel, Switzerland, 2IMS Health Consulting, Brussels, Belgium, 3Health Economics 
and Outcomes Research Ltd, Monmouth, UK
objeCtives: The IMS CORE Diabetes Model (CDM) is a widely published and 
validated decision support tool. The model uses UKPDS68 and UKPDS82 risk 
equations (REs) to predict events and has been updated to include REs from the 
Swedish-National-Diabetes-Registry (S-NDR) and the ADVANCE-Risk-Engine 
(A-RE). The objective of this study was to compare and contrast cardiovascular 
(CV) incidence and cost-effectiveness (CE) across these four REs. Methods: 
Lifetime analyses comparing the CE of metformin+ sulphonylurea (M+S) versus 
metformin + DPP-4 (M+D) was undertaken using the CDM. Basal insulin rescue 
therapy (BI) was applied to both arms at HbA1c threshold levels of 7.5%. Efficacy 
data for dual therapy was sourced from a published mixed treatment compari-
son; HbA1c and BMI change at one-year of -0.8% and 0.199kg/m2 (M+D);-0.79% 
and 0.707kg/m2 (M+S) and -0.82 and 0.545 kg/m2 (BI), respectively, were applied. 
Hypoglycemia rates were taken from the same systematic review. US 2012 costs 
were used and discounting was applied at 3.0%. Results: In the base analysis 
(UKPDS68) predicted CV incidence for myocardial infarction, stroke, ischemic 
heart disease and heart failure was 31.42%, 15.59%, 12.85% and 21.01%, respec-
tively, for patients treated with M+D and 31.39% , 15.23%, 12.51% and 21.26% for 
patients treated with M+S. This compared to 26.72%, 14.31%, 17.96% and 12.74% 
(M+D) and 26.02%, 13.94%, 17.91% and 13.43% (M+S) using UKPDS82 REs; 30.19%, 
52.93%, 6.42% and 6.22% (M+D) and 29.7%, 53.98%, 6.23% and 6.5% (M+S) using 
S-NDR REs and 42.62%, 15.05%, 11.98% and 19.56% (M+D) and 42.17%, 15.1%, 
11.97% and 20.46% (M+S) using A-RE REs. Incremental cost per quality adjusted 
life years were estimated at $78,537 (UKPDS68); $77,594 (UKPDS82); $70,054 
(S-NDR) and $74,783 (A-RE). ConClusions: There was a noteworthy difference 
in predicted CV incidence across the four equations; however, CE results were 
relatively stable. Consequently, choice of RE appears unlikely to significantly 
impact CE.
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objeCtives: Evaluate for the first time in Brazil the pertinence of systematically 
requesting whole-body bone scintigraphy in early-stage HCC adult patients as a 
requisite for inclusion on the waiting list for HTx from a deceased donor, according 
to a reference center in South Brazil. Current pre-transplantation evaluation policy 
includes mandatory bone scintigraphy as a requisite for selecting patients to be 
included on hepatic transplantation list. Previous studies, however, have shown that 
routine scintigraphy is not cost-effective and generates unnecessary Health System 
costs. Methods: We retrospectively analyzed 256 medical files of early-stage HCC 
patients who underwent hepatic transplantation, 187 of whom were subjected to 
pre-transplantation bone scintigraphy. The most common etiology was hepatitis C 
viral infection, the most common liver functional class was Child B, and 78% of the 
patients met the Milan criteria. None of the 187 scintigraphies was positive for metas-
